Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate
The authors studied the effect of the combination of binders on the flow and compressibility characteristics of the agglomerates of binary combination of lactose and dibasic calcium phosphate dihydrate.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 54-64

Evaluation of crushing strength of blank tablets (Y 3 ). PEG has the most significant effect (p < 0.005) on the blank tablets' crushing strength. All the batches exhibiting hardness >100 N showed the presence of PEG. PEG alone, however, may not be a very good binder. The binder may have occupied the voids between the particles, decreasing the porosity of the tablet. Thus the addition of binder with a low yield-pressure value and a relatively small elastic-recovery value (e.g., PEG and PVP) results in tablets of low porosity and high tensile strength (22). The other excipients also tended to increase the hardness of the blank tablet, except acacia.

Evaluation of tablets containing acetaminophen (Y 4 ). Table IV shows that guar gum had the most significant effect on the crushing strength of the tablets containing acetaminophen. HPMC, acacia, and silicon dioxide increased the hardness of acetaminophen-containing tablets, and PEG and starch decreased the hardness of the tablets. Acetaminophen is a poorly compressible drug; therefore, the filler–binder must be robust enough to take up this poorly compressible material and still retain its compressibility. The interaction with the other components of the system might have caused the lower values of coefficients of PEG and starch in the equation for the calculation of CSP. The directly compressible diluent thus behaves in a different manner in presence of acetaminophen. Many researchers have emphasized the fact that the directly compressible diluent behaves differently in presence of drugs; therefore, it is necessary to choose a right directly compressible diluent for a particular drug (23).

2 3 factorial design. The Placket-Burman design indicated that starch, silicon dioxide, and HPMC had pronounced effect on the compressibility index. Starch was a common ingredient affecting the angle of repose and compressibility index. The results of crushing strength indicate that guar gum and polyethylene glycol had predominant effects on the crushing strength of the blank tablets. Guar gum was a common factor affecting the crushing strength of the blank tablets and that of acetaminophen-containing tablets. Hence the 23 factorial design was applied, with starch and guar gum as constant excipients along with the lactose and DCP and hydroxypropyl methylcellulose (A), silicon dioxide (B), and polyethylene glycol (C) were varied at two levels in accordance with the data shown in Table III.

Results from the analysis of data obtained for each response parameter were fitted into a linear polynomial equation of the form

Y = b 0 + aA + bB + cC + abAB + bcBC + caCA + abcABC


Table V: Regression analysis data for the parameters evaluated as per 23 factorial design indicating the values of coefficients for the factors and their interactive terms
in which Y is the level of response parameter, b 0 is the arithmetic average of eight response and a, b, c, ab, bc, ca, and abc are the estimated coefficients for the factors A, B, C and the interaction terms AB, BC, CA and ABC, respectively. ANOVA was performed to eliminate the non-significant terms from the equation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here